PT-141 injections are the FDA-approved form of bremelanotide, sold as Vyleesi. Learn dosing, how fast it works, side effects, and nasal spray alternatives.
PT-141 injections are subcutaneous shots of bremelanotide, a melanocortin receptor agonist that the FDA approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only FDA-approved form of PT-141 in the United States, it is available by prescription only, and it is not approved for men or for postmenopausal women. A single 1.75 mg dose is injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity.
What Is PT-141 (Bremelanotide)?
PT-141 is a synthetic peptide derived from melanotan II, a compound first studied for skin tanning. Researchers noticed that trial participants reported unexpected increases in sexual desire, which shifted the drug's development toward sexual medicine.
Bremelanotide activates melanocortin receptors, mainly MC3R and MC4R, in the central nervous system. That mechanism differs from PDE5 inhibitors like sildenafil, because PT-141 is thought to act on desire pathways in the brain rather than on blood flow alone.
- Drug class: melanocortin receptor agonist peptide
- Brand name: Vyleesi
- Approved route: subcutaneous injection (single-use autoinjector)
- Approved indication: acquired, generalized HSDD in premenopausal women
- Legal status in the US: prescription only; not a dietary supplement
PT-141 is not a hormone, not a vasodilator, and not an FDA-approved treatment for erectile dysfunction.
How PT-141 Injections Work and How Fast They Act
The dose goes into the abdomen or thigh with a prefilled autoinjector. Labeling directs patients to inject at least 45 minutes before anticipated sexual activity, with no more than one dose in a 24-hour period and a maximum of eight doses per month.
That 45-minute lead time is exactly why so many people search pt-141 how long does it take to work before planning a dose. Blood levels of bremelanotide peak roughly an hour after injection, and the half-life is about 2.7 hours, so one shot is not designed to last all day or night.
Efficacy in trials was measured as increased desire and reduced distress over a month of use, not as a guaranteed response to a single injection. Not everyone responds, and approval was based on average improvements across a large study population.
Who PT-141 Injections Are Approved For
Vyleesi is approved for premenopausal women with acquired, generalized HSDD: persistent low sexual desire that causes personal distress and is not limited to one partner or one situation. It is not a treatment for situational desire problems caused by relationship stress, medication, or untreated medical conditions, which a clinician should evaluate first.
PT-141 injections are contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. The medication is not approved for men, and it is not approved for postmenopausal women. Prescribing outside those groups is off-label and rests on limited data.
What About Off-Label Use in Men?
Bremelanotide has been studied in men with erectile dysfunction, including in combination with PDE5 inhibitors, with mixed results. Because there is no FDA-approved male dose, any discussion of pt 141 dosage for men is strictly off-label and should be supervised by a physician.
PT-141 Injection Dosage at a Glance
There is only one approved dose: 1.75 mg, injected subcutaneously as needed. No titration step is required, and taking more does not appear to improve response while it does increase nausea.
| Factor | Approved PT-141 injection (Vyleesi) |
|---|---|
| Dose | 1.75 mg, fixed |
| Route | Subcutaneous, abdomen or thigh |
| Timing | At least 45 minutes before anticipated sexual activity |
| Frequency limit | Maximum one dose per 24 hours; no more than 8 doses per month |
| Titration | None required |
If a dose is missed, patients are advised not to stack doses. Simply wait until the next appropriate occasion.
PT-141 Nasal Spray vs Injection
Earlier clinical trials tested an intranasal bremelanotide formulation, but the product that reached FDA approval is the subcutaneous injection. Nasal sprays sold online as PT-141 are not FDA-approved, and their absorption is far more variable than an injected dose.
| Feature | PT-141 injection | PT-141 nasal spray |
|---|---|---|
| FDA status | Approved (Vyleesi) | Not approved |
| Dose accuracy | Fixed 1.75 mg per autoinjector | Variable; depends on device and technique |
| Onset | Roughly 45 to 60 minutes | Inconsistent in older trials |
| Source | Licensed pharmacy, with a prescription | Often sold as research-use-only material |
If you are weighing convenience against predictability, the pt-141 nasal spray vs injection trade-off usually comes down to dose reliability rather than price alone.
PT-141 Side Effects and Safety
Nausea is the most commonly reported side effect, affecting roughly 40% of trial participants, and it often eases with repeated use. Flushing, headache, vomiting, and injection-site reactions are also common.
Bremelanotide can cause a short-lived rise in blood pressure and a small drop in heart rate after each dose. Post-marketing reports also describe focal hyperpigmentation, including new or darkened moles and freckles, so patients should check their skin and report changes.
Anyone tracking pt 141 peptide side effects should keep a simple log of timing, symptoms, and duration to share with a clinician. Because nausea is dose-related and some patients find alcohol makes it worse, many providers suggest limiting drinking on days a dose is used.
PT-141 has not been studied in pregnancy, and it should not be used during pregnancy or breastfeeding without a clinician's guidance.
Prescription Vyleesi vs Research-Use PT-141
Search results for PT-141 often mix clinical information with vendor pages selling vials labeled "not for human consumption." Those products are not approved for human use, and the FDA does not verify their identity, purity, or sterility.
Online pt-141 peptide reviews are anecdotal and rarely verifiable, and public forum threads cannot confirm what is actually inside an unregulated vial. Injecting a mislabeled or contaminated peptide carries real risk of infection, allergic reaction, and dosing errors.
| Factor | Prescription Vyleesi | Research-use PT-141 vials |
|---|---|---|
| FDA approval | Yes, for HSDD in premenopausal women | No |
| Quality testing | Enforced manufacturing and sterility standards | Not verified by the FDA |
| Dose accuracy | Fixed 1.75 mg autoinjector | Requires home reconstitution and measurement |
| Medical oversight | Prescriber and pharmacist involved | Usually none |
Cost and insurance coverage push some patients toward the gray market, but a clinician may be able to help with prior authorization or alternative options.
What to Discuss With a Clinician First
PT-141 injections are a prescription treatment with a defined approved population, a fixed 1.75 mg dose, and a well-documented side effect profile. A short conversation before starting can prevent most problems.
- Whether your symptoms actually meet the criteria for HSDD
- Your blood pressure and cardiovascular history
- Other medications, including antidepressants and antihypertensives
- What a realistic response looks like, and when to stop treatment
Anyone considering PT-141, or an unapproved nasal or research-grade version of it, should start with a healthcare professional rather than an online vendor.
Frequently Asked Questions
How long does PT-141 take to work after an injection?
PT-141 injections are labeled to be given at least 45 minutes before anticipated sexual activity. In pharmacokinetic studies, bremelanotide blood levels peak about an hour after dosing, and the half-life is roughly 2.7 hours. Some people notice effects sooner, and others do not respond at all, since approval was based on average improvements across a study population rather than a guaranteed result from one dose.
What are the most common side effects of PT-141 injections?
Nausea is the most common side effect, reported by roughly 40% of clinical trial participants, followed by flushing, headache, vomiting, and injection-site reactions. Bremelanotide can also cause a brief rise in blood pressure and a small drop in heart rate after dosing. Post-marketing reports describe darkened skin patches or moles, so any new or changing skin lesion should be reported to a healthcare professional.
Is PT-141 approved for men?
No. The FDA approved PT-141 (Vyleesi) only for premenopausal women with hypoactive sexual desire disorder. Bremelanotide has been studied in men with erectile dysfunction, sometimes alongside PDE5 inhibitors, but results were mixed and no male dose is approved. Any use in men is off-label and requires a prescriber's supervision.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.